Therefore, to avoid the unfavorable decrease in muscle mass, the administration of SGLT2 inhibitors should be carefully considered in patients with diabetes who are at a high risk for sarcopenia, especially in elderly patients with diabetes. Here, SLC5A2 is linked to sarcopenia.